Dynamic Biomolecules in Neurodegeneration: From Structural Mechanisms to Drug Discovery

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 7221

Special Issue Editor


E-Mail Website
Guest Editor
Center for Biotechnology and Interdisciplinary Studies, Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, NY 12180, USA
Interests: NMR; Abeta; Alzheimer’s disease; tau; drug discovery; p53; Hedgehog; glycan; sulfating

Special Issue Information

Dear Colleagues,

Neurodegenerative diseases, such as Alzheimer’s disease and related dementia, have tremendous societal impacts, affecting millions of people worldwide. However, few disease-modifying therapeutic options are available, underlying the urgent need for a better understanding of the molecular mechanisms of neurodegeneration. Neurodegenerative pathologies often feature highly flexible molecules, such as amyloid b-peptide, tau, a-synuclein, and glycan, which pose a particular challenge for structural characterization and drug discovery. NMR and computational biology are especially suited to these molecules, due to their unique ability to study molecular dynamics at high resolution. NMR and simulation are also indispensable tools for drug discovery against flexible molecules. In this Special Issue, I would like to invite you to submit your latest results and insights in this area of research, either as an original research article or a review paper.

Prof. Dr. Chunyu Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Alzheimer’s disease
  • tauopathy
  • neurodegeneration
  • NMR
  • computational biology
  • Tau
  • amyloid
  • structural biology
  • drug discovery
  • dynamics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

24 pages, 1693 KiB  
Review
New Insights into lncRNAs in Aβ Cascade Hypothesis of Alzheimer’s Disease
by Yitong Hao, Bo Xie, Xiaoshu Fu, Rong Xu and Yu Yang
Biomolecules 2022, 12(12), 1802; https://doi.org/10.3390/biom12121802 - 2 Dec 2022
Cited by 10 | Viewed by 2714
Abstract
Alzheimer’s disease (AD) is the most common type of dementia, but its pathogenesis is not fully understood, and effective drugs to treat or reverse the progression of the disease are lacking. Long noncoding RNAs (lncRNAs) are abnormally expressed and deregulated in AD and [...] Read more.
Alzheimer’s disease (AD) is the most common type of dementia, but its pathogenesis is not fully understood, and effective drugs to treat or reverse the progression of the disease are lacking. Long noncoding RNAs (lncRNAs) are abnormally expressed and deregulated in AD and are closely related to the occurrence and development of AD. In addition, the high tissue specificity and spatiotemporal specificity make lncRNAs particularly attractive as diagnostic biomarkers and specific therapeutic targets. Therefore, an in-depth understanding of the regulatory mechanisms of lncRNAs in AD is essential for developing new treatment strategies. In this review, we discuss the unique regulatory functions of lncRNAs in AD, ranging from Aβ production to clearance, with a focus on their interaction with critical molecules. Additionally, we highlight the advantages and challenges of using lncRNAs as biomarkers for diagnosis or therapeutic targets in AD and present future perspectives in clinical practice. Full article
Show Figures

Figure 1

20 pages, 1628 KiB  
Review
Heparan Sulfate Proteoglycans in Tauopathy
by Yanan Zhu, Lauren Gandy, Fuming Zhang, Jian Liu, Chunyu Wang, Laura J. Blair, Robert J. Linhardt and Lianchun Wang
Biomolecules 2022, 12(12), 1792; https://doi.org/10.3390/biom12121792 - 30 Nov 2022
Cited by 13 | Viewed by 3970
Abstract
Tauopathies are a class of neurodegenerative diseases, including Alzheimer’s disease, and are characterized by intraneuronal tau inclusion in the brain and the patient’s cognitive decline with obscure pathogenesis. Heparan sulfate proteoglycans, a major type of extracellular matrix, have been believed to involve in [...] Read more.
Tauopathies are a class of neurodegenerative diseases, including Alzheimer’s disease, and are characterized by intraneuronal tau inclusion in the brain and the patient’s cognitive decline with obscure pathogenesis. Heparan sulfate proteoglycans, a major type of extracellular matrix, have been believed to involve in tauopathies. The heparan sulfate proteoglycans co-deposit with tau in Alzheimer’s patient brain, directly bind to tau and modulate tau secretion, internalization, and aggregation. This review summarizes the current understanding of the functions and the modulated molecular pathways of heparan sulfate proteoglycans in tauopathies, as well as the implication of dysregulated heparan sulfate proteoglycan expression in tau pathology and the potential of targeting heparan sulfate proteoglycan-tau interaction as a novel therapeutic option. Full article
Show Figures

Figure 1

Back to TopTop